Event-dense runway: management frames the coming quarters as a calendar of its own named, scheduled events
The model's full reasoning — Q1 2018 call → NOWe need to determine if management frames the near future as a calendar of specific, named, already-scheduled events. The transcript includes several forward-looking statements. Let's identify specific events with timing. - iSeq: "expect to scale shipments midyear" - that's a specific event. - NovaSeq: "NovaSeq upgrade cycle will span multiple years" - not a specific event. - S1 flow cell: "officially launched at AGBT in mid-February... expected to ramp throughout 2018" - that's a ramp, but timing is vague. - Harvard Pilgrim NIPT study: "launched a new study... to collect data... test runs about 18 months... back half of next year" - that's a data readout, but it's more than a few quarters out? Actually "back half of next year" is 2019, so not near future. - UK Biobank: "announced that it will be sequencing 50,000 whole genomes over the next two years" - that's a program, but not a near-term event. - Genomics England: "now halfway through its 100,000 genome target and hopes to complete sequencing all 100,000 genomes this year" - that's a completion this year, but not a specific quarter. - Oncology collaborations with Loxo and BMS: "multi-year collaborations... milestones... over the course of the next couple of years" - not near-term specific. - 23andMe approval: that's external, not company's own event. - Microarray: "spectacular start" - not a future event. Management also mentions "we are planning some incremental R&D and commercial projects to capitalize on the momentum" - that's vague. The question asks: does management frame the near future as a calendar of its own specific, named, already-scheduled events? The events mentioned are mostly either vague (ramp throughout 2018) or long-term (back half of next year, over next two years). The iSeq scaling midyear is one specific event. But is there a sequence of multiple distinct events? Possibly the S1 ramp, iSeq scale, but those are not clearly time-anchored with specific dates. The call's forward energy is more about current momentum and demand trends rather than a schedule of upcoming events. Management discusses guidance, but not a calendar of events. The answer is likely NO. We need to be strict: multiple distinct company-specific events with rough timing, and management treats that sequence as the main engine.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| RCEL | AVITA Medical, Inc. | Q1 2024 | 2024-05-14 | F |
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| BEAT | BioTelemetry's | Q4 2022 | 2023-03-17 | D |
| ARWR | Arrowhead Pharmaceuticals, Inc. | Q4 2022 | 2022-11-28 | D |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| ASTS | AST SpaceMobile, Inc. | Q2 2022 | 2022-08-15 | D |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| ALKS | Alkermes plc | Q3 2018 | 2018-10-23 | C |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| ITCI | Intra-Cellular Therapies, Inc. | Q4 2017 | 2018-03-01 | D |
| PCRX | Pacira BioSciences, Inc. | Q4 2017 | 2018-02-28 | C |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FATE | Fate Therapeutics, Inc. | Q3 2016 | 2016-11-07 | C |
| DUK | Duke Energy Corporation | Q2 2016 | 2016-08-04 | B |
PCRX · Q4 2017 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management frames the near-term outlook (2018) as a concrete calendar of its own named, time-anchored events—nerve-block label expansion, C-section study readout, additional Phase 4 study launches, CMS reimbursement decisions, and new partnerships—treating the execution of this sequence as the primary driver of 2018 growth and strategic progress. These are presented as scheduled company actions rather than general market trends, with explicit timing (e.g., mid-year FDA meetings, second-half manufacturing ramp, AAOS programs) and positioned as the central story of where the company is heading.
AU · Q2 2018 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management structures the forward outlook around a clear sequence of its own named, time-anchored events—Kibali underground ramp-up and Azambi hydropower station (Q3), Siguiri CIL circuit and power plants (Q4), Obuasi redevelopment milestones (first gold end-2019), Mponeng 6-month backfill plant start (H2), South Africa Section 189 process and wage negotiations (Q3), plus production upticks at multiple sites—presenting these as the primary drivers of the next stage rather than generic market or cost themes.
HROW · Q4 2021 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES The transcript shows management organizing the near-term outlook around a clear sequence of its own named, time-anchored events: AMP-100 PDUFA on October 16 (with launch a few months later), Surface Opthalmics data readout in a few months, Melt Pharmaceuticals top-line data soon after, and internal product 18-month launches, plus MAQ-100 FDA meeting mid-year and relaunch preparations for IOPIDINE/MAXITROL/MOXEZA.